Meeting
2018 ASCO Annual Meeting
Phase Ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors.
Authors
Toshio Kubo
Center for Clinical Oncology, Okayama University Hospital, Okayama, Japan
Toshio Kubo , Katsuyuki Hotta , Takashi Ninomiya , Hironari Kato , Shigeru Horiguchi , Atsushi Takamoto , Toshiyuki Kozuki , Naoyuki Nogami , Hiroshi Ishii , Tomohiro Nishina , Daijiro Harada , Shinichi Toyooka , Hiroyuki Okada , Toshiyoshi Fujiwara , Heiichiro Udono , Katsuyuki Kiura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
000028405
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS3119)
DOI
10.1200/JCO.2018.36.15_suppl.TPS3119
Abstract #
TPS3119
Poster Bd #
324a
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors.
First Author: Toshihiko Doi
Poster
2023 ASCO Annual Meeting
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.
First Author: Krish Patel
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2022 ASCO Annual Meeting
Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.
First Author: Xiao-Li Wei